AstraZeneca to buy Amolit Pharma for $1.05bn to boost rare disease portfolio
Drug maker AstraZeneca said on Thursday it will acquire rare endocrine disease company Amolyt Pharma for $1.05 billion in cash in a bid to boost its rare disease portfolio.
POPULAR POSTS
Trump opts for personal ties to choose his government team
November 15, 2024
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
LIVE STREAM
